Literature DB >> 10726629

The effects of tamoxifen therapy on the endometrium.

G Zarbo1, G Caruso, M Zammitti, S Caruso, R Zarbo.   

Abstract

From January 1992 to December 1998, 219 women (aged between 30 and 81 yrs; average 55 years) affected by breast cancer were treated. These women in addition to the usual adjuvant therapy, were treated with TAM 20 mg/day, for a period between 24 and 72 months (average 40). In this group there were 84 postmenopausal and 31 premenopausal women. In 8 fertile patients ovarian activity was suppressed with GnRh analogue therapy and one patient underwent attinic castration. Before performing TAM therapy, a hysteroscopic exam was done and patients were followed-up with an annual check-up. None had any endometrial side-effects after the first check-up. After two years, 31 women (26.9%) complained of endometrial alterations (hyperplasia, polyps and endometrial cancer). One women only after 6 years of follow-up, had metrorrhagia; an endometrial adenocarcinoma was found. We would like to point out the necessity of monitoring these patients with an annual check-up (transvaginal sonography and/or hysteroscopy).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726629

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  4 in total

Review 1.  Challenges in the gynecologic care of premenopausal women with breast cancer.

Authors:  Jamie N Bakkum-Gamez; Shannon K Laughlin; Jani R Jensen; Clement O Akogyeram; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-02-09       Impact factor: 7.616

2.  Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases.

Authors:  Clelia Madeddu; Giulia Gramignano; Paraskevas Kotsonis; Francesco Paribello; Antonio Macciò
Journal:  Oncol Lett       Date:  2014-07-04       Impact factor: 2.967

3.  Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients.

Authors:  Peter Rambau; Nestory Masalu; Kahima Jackson; Philipo Chalya; Patrizia Serra; Sara Bravaccini
Journal:  BMC Res Notes       Date:  2014-06-26

4.  Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Authors:  Ronald K Potkul; Joseph M Unger; Robert B Livingston; Katherine D Crew; Sharon P Wilczynski; Caryl G Salomon; Barbara L Smith; Lucas Wong; David L Campbell; David E Einspahr; Garnet L Anderson; Dawn Hershman; Gary E Goodman; Powel H Brown; Frank L Meyskens; Kathy S Albain
Journal:  NPJ Breast Cancer       Date:  2016-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.